Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.64 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.64 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.54 |
| ▸ | YAP1 | P46937 | 3/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321185 | 0.91 | S1PR1 (0.64) | S1PR5S1PR1S1PR3YAP1ESR2 | |
| SCHEMBL322105 | 0.84 | ESR2 (0.60) | S1PR5S1PR1S1PR3ESR2MAPK1 | |
| SCHEMBL15166548 | 0.83 | S1PR5 (0.64) | S1PR5S1PR1S1PR3YAP1PRMT5 | |
| SCHEMBL321390 | 0.83 | S1PR5 (0.81) | S1PR5S1PR1S1PR3YAP1HIF1A | |
| SCHEMBL320686 | 0.81 | ESR2 (0.50) | S1PR5S1PR1S1PR3ESR2MAPK1 | |
| SCHEMBL18550482 | 0.81 | MAPT (0.54) | S1PR5YAP1PRMT5MAPK1GCK | |
| SCHEMBL23684926 | 0.80 | ESR2 (0.64) | YAP1ESR2MAPK1NR1H2GHSR | |
| SCHEMBL30199590 | 0.80 | NR1H2 (0.60) | YAP1ESR2MAPK1NR1H2GHSR | |
| SCHEMBL15164304 | 0.80 | S1PR5 (0.66) | S1PR5S1PR1S1PR3PRMT5HIF1A | |
| SCHEMBL15164301 | 0.80 | S1PR5 (0.69) | S1PR5S1PR1S1PR3PRMT5PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48301-E1 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2020-11-10 | — | — | US | disclosed |
| EP-2590980-B1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2017-09-20 | — | — | EP | disclosed |
| EP-2590980-B1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2017-09-20 | — | — | EP | disclosed |
| US-9670220-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-06-06 | — | — | US | disclosed |
| US-9670220-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-06-06 | — | — | US | disclosed |
| US-20150284403-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-08 | — | — | US | disclosed |
| US-20150284403-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-08 | — | — | US | disclosed |
| US-9096612-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| US-9096612-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| US-8796262-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2014-08-05 | — | — | US | disclosed |
| US-8796262-B2 | Fused heterocyclic derivatives as S1P modulators | ABBVIE B.V. (NL) | 2014-08-05 | — | — | US | disclosed |
| US-20140066433-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE INC (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066433-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE INC (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130203737-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-08 | — | — | US | disclosed |
| US-20130203737-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-08 | — | — | US | disclosed |
| EP-2590980-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004373-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004373-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066433-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | S1PR5, S1PR1, S1PR3 | S1PR5 1/4885S1PR1 2/4885S1PR3 3/4885 |
| US-20130203737-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | S1PR5 5/4885S1PR1 2/4885S1PR3 1/4885 |
| US-20150284403-A1 | FUSED HETEROCYCLIC DERIVATIVES AS S1P MODULATORS | S1PR5, S1PR1, S1PR3 | S1PR5 1/4885S1PR1 2/4885S1PR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.